More Post from the Author
- Workshop Debuts Four New AI Features, Positioning Itself as the Clear Leader in AI for Internal Communications
- r4 Technologies Donates Smart Food AI Program to Help States Feed SNAP Beneficiaries
- Armor Health's Data Driven Approach to Patient Care Helps Secure Agreement to Provide Correctional Healthcare Service for Inmates in Bell County Texas
- Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
- ENERGIZER HOLDINGS, INC. DECLARES QUARTERLY DIVIDEND ON ITS COMMON STOCK
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes
Published on Wed 12 Feb 2025 8:07:04 UTC
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:
Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
SOURCE Indivior PLC
More Post from the Author
- Workshop Debuts Four New AI Features, Positioning Itself as the Clear Leader in AI for Internal Communications
- r4 Technologies Donates Smart Food AI Program to Help States Feed SNAP Beneficiaries
- Armor Health's Data Driven Approach to Patient Care Helps Secure Agreement to Provide Correctional Healthcare Service for Inmates in Bell County Texas
- Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
- ENERGIZER HOLDINGS, INC. DECLARES QUARTERLY DIVIDEND ON ITS COMMON STOCK